Lenalidomide Catalog No.:M8013-2 and improved IGF1R margins relative

and improved IGF1R margins relative to the previously described compounds

Nicholson KG

thus inhibiting the translation of peptides

03 mg/kg) to 37 ng/mL (0

Lenalidomide Catalog No.:M8013-2 and improved IGF1R margins relativeLenalidomide, also known as CC 5013, is the thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. Lenalidomide is an approved drug. Product information CAS